Online Program

Return to main conference page
Wednesday, September 25
Wed, Sep 25, 9:45 AM - 10:30 AM
Marriott Foyer
Poster Session

Probability of Study Success (PrSS) Evaluation Based on Multiple Endpoints in Immuno-Oncology (IO) (300888)

*Yong Lin, Eli-Lilly and Company 
Jingyi Liu, Eli Lilly and Company 
Zhen Zhang, Eli Lilly and Company 

Keywords: Immuno-oncology, Probability of Study Success, Composit endpoints, Go/no-go decision

IO drug(s), due to its mechanism of action, may demonstrate marginal benefit in Progression Free Survival (PFS) but meaningful improvement in Overall Survival (OS). To mitigate the risk, sponsors often consider PFS and OS as co-primary in phase III development. This unique feature brings challenges to constructing a go/no-go decision boundary in phase 2 study. To accelerate the development due to the highly competitive landscape, sponsors sometimes would like to trigger a phase 3 trial based on strong phase 2 interim PFS and overall response rate (ORR) results while continuing the follow-up of OS.

To accommodate this risk, we propose a Bayesian joint modeling approach that utilizes composite endpoints (e.g. PFS and OS) at early stage for phase II to evaluate PrSS of PhIII study. The model assumes the hazard ratio of PFS and OS are bivariate log-normally distributed with certain correlation. The correlation can be evaluated based on two distinctive approaches, a) retrieving from historical data, and b) conducting simulations. PrSS of phase 3 study based on composite endpoints (e.g. HR_PFS Numerical outcomes and a clinical trial example utilizing this approach in clinical development will be described to demonstrate the merits of the joint modeling approach.